Cover Image
市場調查報告書

大腸癌:開發中產品分析

Colorectal Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232768
出版日期 內容資訊 英文 1645 Pages
訂單完成後即時交付
價格
Back to Top
大腸癌:開發中產品分析 Colorectal Cancer - Pipeline Review, H2 2016
出版日期: 2016年12月28日 內容資訊: 英文 1645 Pages
簡介

大腸癌是由結腸或直腸開始發病的癌症,其症狀有下痢及便秘、血便、激烈腹痛、滿腹感及膨脹感、原因不明的體重減輕、倦怠感、噁心、嘔吐等。罹患大腸癌的原因有吸煙、第二型糖尿病、容易罹患大腸癌的家族病史等。

本報告提供大腸癌症治療藥的開發中產品概要和臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

大腸癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

大腸癌:企業開發中的治療藥

大腸癌:大學/機關研究中的治療藥

大腸癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

大腸癌:企業開發中的產品

大腸癌:大學/機關研究中的產品

大腸癌的治療藥的開發企業

大腸癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

大腸癌:暫停中的計劃

大腸癌:開發中止的產品

大腸癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8870IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2016, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 26, 106, 110, 9, 145, 36 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 15, 8, 22 and 3 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Colorectal Cancer Overview
  • Therapeutics Development
  • Colorectal Cancer - Therapeutics under Development by Companies
  • Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes
  • Colorectal Cancer - Pipeline Products Glance
  • Colorectal Cancer - Products under Development by Companies
  • Colorectal Cancer - Products under Investigation by Universities/Institutes
  • Colorectal Cancer - Companies Involved in Therapeutics Development
  • Colorectal Cancer - Therapeutics Assessment
  • Drug Profiles
  • Colorectal Cancer - Dormant Projects
  • Colorectal Cancer - Discontinued Products
  • Colorectal Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Colorectal Cancer, H2 2016
  • Number of Products under Development for Colorectal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Colorectal Cancer - Pipeline by 2cureX ApS, H2 2016
  • Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016
  • Colorectal Cancer - Pipeline by 3SBio Inc, H2 2016
  • Colorectal Cancer - Pipeline by 4SC AG, H2 2016
  • Colorectal Cancer - Pipeline by AB Science SA, H2 2016
  • Colorectal Cancer - Pipeline by AbbVie Inc, H2 2016
  • Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2016
  • Colorectal Cancer - Pipeline by Accelerated Pharma Inc, H2 2016
  • Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2016
  • Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2016
  • Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Colorectal Cancer - Pipeline by Alchemia Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Allinky Biopharma, H2 2016
  • Colorectal Cancer - Pipeline by Amal Therapeutics SA, H2 2016
  • Colorectal Cancer - Pipeline by amcure GmbH, H2 2016
  • Colorectal Cancer - Pipeline by Amgen Inc, H2 2016
  • Colorectal Cancer - Pipeline by Antibe Therapeutics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Apexigen Inc, H2 2016
  • Colorectal Cancer - Pipeline by Aphios Corp, H2 2016
  • Colorectal Cancer - Pipeline by Aposense Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by ArQule Inc, H2 2016
  • Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2016
  • Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2016
  • Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2016
  • Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Colorectal Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
  • Colorectal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2016
  • Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
  • Colorectal Cancer - Pipeline by Bayer AG, H2 2016
  • Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2016
  • Colorectal Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Biocon Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Bionomics Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Bionovis SA, H2 2016
  • Colorectal Cancer - Pipeline by Biotecnol Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2016
  • Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Colorectal Cancer - Pipeline by Boston Biomedical Inc, H2 2016
  • Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Colorectal Cancer - Pipeline by Burzynski Research Institute Inc, H2 2016
  • Colorectal Cancer - Pipeline by Calithera Biosciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Carna Biosciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016
  • Colorectal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2016
  • Colorectal Cancer - Pipeline by Celgene Corp, H2 2016
  • Colorectal Cancer - Pipeline by Cellceutix Corp, H2 2016
  • Colorectal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by Celltrion Inc, H2 2016
  • Colorectal Cancer - Pipeline by Celyad SA, H2 2016
  • Colorectal Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
  • Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Colorectal Cancer - Pipeline by ChoDang Pharm Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Cipla Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Cleave Biosciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by Cleveland BioLabs Inc, H2 2016
  • Colorectal Cancer - Pipeline by COARE Biotechnology Inc, H2 2016
  • Colorectal Cancer - Pipeline by Coherus BioSciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by Compugen Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016
  • Colorectal Cancer - Pipeline by CrystalGenomics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Cytune Pharma SAS, H2 2016
  • Colorectal Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H2 2016
  • Colorectal Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
  • Colorectal Cancer - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
  • Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
  • Colorectal Cancer - Pipeline by EirGenix Inc, H2 2016
  • Colorectal Cancer - Pipeline by Eisai Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Colorectal Cancer - Pipeline by Endor Nanotechnologies SL, H2 2016
  • Colorectal Cancer - Pipeline by enGene Inc, H2 2016
  • Colorectal Cancer - Pipeline by EnGeneIC Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Ensol Biosciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by EntreChem SL, H2 2016
  • Colorectal Cancer - Pipeline by Enzo Biochem Inc, H2 2016
  • Colorectal Cancer - Pipeline by Etubics Corp, H2 2016
  • Colorectal Cancer - Pipeline by Exelixis Inc, H2 2016
  • Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Formosa Laboratories Inc, H2 2016
  • Colorectal Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Genentech Inc, H2 2016
  • Colorectal Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Genoscience Pharma, H2 2016
  • Colorectal Cancer - Pipeline by Genzyme Corp, H2 2016
  • Colorectal Cancer - Pipeline by Gilead Sciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Colorectal Cancer - Pipeline by Glycotope GmbH, H2 2016
  • Colorectal Cancer - Pipeline by Golden Biotechnology Corp, H2 2016
  • Colorectal Cancer - Pipeline by Green Cross Corp, H2 2016
  • Colorectal Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Handok Inc, H2 2016
  • Colorectal Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Heat Biologics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2016
  • Colorectal Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016
  • Colorectal Cancer - Pipeline by iDD biotech SAS, H2 2016
  • Colorectal Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016
  • Colorectal Cancer - Pipeline by Ignyta Inc, H2 2016
  • Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd, H2 2016
  • Colorectal Cancer - Pipeline by ImmuneXcite Inc, H2 2016
  • Colorectal Cancer - Pipeline by Immunomedics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Immunovative Therapies Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Incanthera Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Incyte Corp, H2 2016
  • Colorectal Cancer - Pipeline by Innovent Biologics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Interprotein Corp, H2 2016
  • Colorectal Cancer - Pipeline by Intezyne Technologies Inc, H2 2016
  • Colorectal Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by IPD Therapeutics BV, H2 2016
  • Colorectal Cancer - Pipeline by Isofol Medical AB, H2 2016
  • Colorectal Cancer - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by JHL Biotech Inc, H2 2016
  • Colorectal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Colorectal Cancer - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Kancera AB, H2 2016
  • Colorectal Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Kura Oncology Inc, H2 2016
  • Colorectal Cancer - Pipeline by Laboratorio ELEA SACIF y A, H2 2016
  • Colorectal Cancer - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Lion Biotechnologies Inc, H2 2016
  • Colorectal Cancer - Pipeline by LipoMedix Pharmaceutical Inc, H2 2016
  • Colorectal Cancer - Pipeline by Loxo Oncology, Inc., H2 2016
  • Colorectal Cancer - Pipeline by Mabion SA, H2 2016
  • Colorectal Cancer - Pipeline by Mabtech Ltd, H2 2016
  • Colorectal Cancer - Pipeline by mAbxience SA, H2 2016
  • Colorectal Cancer - Pipeline by MacroGenics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Marina Biotech Inc, H2 2016
  • Colorectal Cancer - Pipeline by MediaPharma srl, H2 2016
  • Colorectal Cancer - Pipeline by MedImmune LLC, H2 2016
  • Colorectal Cancer - Pipeline by Medinet Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Merck & Co Inc, H2 2016
  • Colorectal Cancer - Pipeline by Merck KGaA, H2 2016
  • Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Merus NV, H2 2016
  • Colorectal Cancer - Pipeline by Microlin Bio, Inc., H2 2016
  • Colorectal Cancer - Pipeline by MolMed SpA, H2 2016
  • Colorectal Cancer - Pipeline by Mologen AG, H2 2016
  • Colorectal Cancer - Pipeline by Morphotek Inc, H2 2016
  • Colorectal Cancer - Pipeline by Multimmune GmbH, H2 2016
  • Colorectal Cancer - Pipeline by Mycenax Biotech Inc, H2 2016
  • Colorectal Cancer - Pipeline by Natco Pharma Ltd, H2 2016
  • Colorectal Cancer - Pipeline by NatureWise Biotech & Medicals Corp, H2 2016
  • Colorectal Cancer - Pipeline by Nektar Therapeutics, H2 2016
  • Colorectal Cancer - Pipeline by Neovacs SA, H2 2016
  • Colorectal Cancer - Pipeline by Nerviano Medical Sciences Srl, H2 2016
  • Colorectal Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016
  • Colorectal Cancer - Pipeline by NormOxys Inc, H2 2016
  • Colorectal Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Novartis AG, H2 2016
  • Colorectal Cancer - Pipeline by Novogen Ltd, H2 2016
  • Colorectal Cancer - Pipeline by Noxxon Pharma AG, H2 2016
  • Colorectal Cancer - Pipeline by NuCana BioMed Ltd, H2 2016
  • Colorectal Cancer - Pipeline by OBI Pharma Inc, H2 2016
  • Colorectal Cancer - Pipeline by Oncobiologics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016
  • Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016
  • Colorectal Cancer - Pipeline by Onconova Therapeutics Inc, H2 2016
  • Colorectal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016

List of Figures

  • Number of Products under Development for Colorectal Cancer, H2 2016
  • Number of Products under Development for Colorectal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top